Anti-fibrotic effect of aurocyanide, the active metabolite of auranofin.
Ontology highlight
ABSTRACT: Drug repositioning has gained significant attention over the past several years. The anti-rheumatoid arthritis drug auranofin has been investigated for the treatment of other diseases, including liver fibrosis. Because auranofin is rapidly metabolized, it is necessary to identify the active metabolites of auranofin that have detectable levels in the blood and reflect its therapeutic effects. In the present study, we investigated whether aurocyanide as an active metabolite of auranofin, can be used to evaluate the anti-fibrotic effects of auranofin. Incubation of auranofin with liver microsomes showed that auranofin was susceptible to hepatic metabolism. Previously, we found that the anti-fibrotic effects of auranofin are mediated via system xc--dependent inhibition of
SUBMITTER: Kim HY
PROVIDER: S-EPMC9998255 | biostudies-literature | 2023 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA